Treating moderate to severe psoriasis - best use of biologics.

Hdl Handle:
http://hdl.handle.net/10147/335812
Title:
Treating moderate to severe psoriasis - best use of biologics.
Authors:
Lynch, Maeve; Kirby, Brian; Warren, Richard B
Affiliation:
Dermatology Department, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Citation:
Lynch, M., Kirby, B., Warren, R.B., 2014. Treating moderate to severe psoriasis - best use of biologics. Expert Review of Clinical Immunology, 10 (2) pp 269-79
Journal:
Expert review of clinical immunology
Issue Date:
Feb-2014
URI:
http://hdl.handle.net/10147/335812
DOI:
10.1586/1744666X.2014.873701
PubMed ID:
24372444
Additional Links:
http://informahealthcare.com/doi/abs/10.1586/1744666X.2014.873701
Abstract:
This review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics.
Item Type:
Article
Language:
en
Keywords:
SKIN DISORDER
Local subject classification:
PSORIASIS
MeSH:
Animals; Antibodies, Monoclonal; Biological Therapy; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Interleukin-17; Practice Guidelines as Topic; Psoriasis; Receptors, Interleukin-17
ISSN:
1744-8409

Full metadata record

DC FieldValue Language
dc.contributor.authorLynch, Maeveen_GB
dc.contributor.authorKirby, Brianen_GB
dc.contributor.authorWarren, Richard Ben_GB
dc.date.accessioned2014-11-19T13:00:38Z-
dc.date.available2014-11-19T13:00:38Z-
dc.date.issued2014-02-
dc.identifier.citationLynch, M., Kirby, B., Warren, R.B., 2014. Treating moderate to severe psoriasis - best use of biologics. Expert Review of Clinical Immunology, 10 (2) pp 269-79en_GB
dc.identifier.issn1744-8409-
dc.identifier.pmid24372444-
dc.identifier.doi10.1586/1744666X.2014.873701-
dc.identifier.urihttp://hdl.handle.net/10147/335812-
dc.description.abstractThis review focuses on the efficacy, safety and best use of biologic agents in moderate-to-severe psoriasis. Recommendations from two recent guidelines are summarised. The NICE Guidelines 2012 provide recommendations on best practice for prescribing biologics. The German S3 Guidelines are based on a systematic review of published studies and report the efficacy of biologics and guidelines for treatment. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. Registry data is evolving and will provide data on safety to help inform long-term monitoring of patients with psoriasis on biologics agents. New anti-interleukin-17 (IL17) and anti-IL17RA biologics are in Phase 3 clinical trials and may prove to be more effective than existing biologics.en_GB
dc.language.isoenen
dc.relation.urlhttp://informahealthcare.com/doi/abs/10.1586/1744666X.2014.873701en_GB
dc.rightsArchived with thanks to Expert review of clinical immunologyen_GB
dc.subjectSKIN DISORDERen_GB
dc.subject.meshAnimals-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshBiological Therapy-
dc.subject.meshClinical Trials, Phase III as Topic-
dc.subject.meshDisease Progression-
dc.subject.meshHumans-
dc.subject.meshInterleukin-17-
dc.subject.meshPractice Guidelines as Topic-
dc.subject.meshPsoriasis-
dc.subject.meshReceptors, Interleukin-17-
dc.subject.otherPSORIASISen_GB
dc.titleTreating moderate to severe psoriasis - best use of biologics.en_GB
dc.typeArticleen
dc.contributor.departmentDermatology Department, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.en_GB
dc.identifier.journalExpert review of clinical immunologyen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.